The new HemoCue Albumin 201 allows fast, simple and accurate screening for microalbuminuria at the point of care
Using a drop of urine from a spot or timed sample, HemoCue says its new Albumin 201 provides quantitative lab quality results in seconds.
With a range of user-friendly features, including sophisticated data management and QC options, the new system can be used in any healthcare environment for screening, diagnosis and monitoring.
The presence of microalbumin in the urine is the earliest risk marker of kidney and cardiovascular damage caused by diabetes and the National Services Framework (NSF) for Diabetes and NICE guidelines stipulate six monthly testing for all diabetic patients.
Early detection of microalbuminuria allows treatment that can slow or prevent the onset of both diabetic nephropathy and cardiovascular disease.
The HemoCue Albumin 201 is easy to use and requires no laboratory training.
The test utilises convenient disposable cuvettes which have a long shelf life at room temperature and contain all of the reagents in a dried form.
Sample is automatically drawn into the cuvette by capillary action and spontaneously mixes with the reagents - it is then simply inserted into the portable HemoCue analyser and results are clearly displayed within 90 seconds.
A recently published MHRA evaluation confirmed that, at just £1.75 for each microalbuminuria screen, the HemoCue Albumin 201 represents excellent value for money and is almost half the cost of the nearest alternative.
